| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HP40; Il9; Interleukin 9 MCGF; P40; TCGF 3;;IL 9 |
| WB Predicted band size | Calculated MW: 16 kDa ; Observed MW: 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL 9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4条关于IL9抗体的示例参考文献(内容为模拟概括，仅供参考)：
1. **标题**：*Anti-IL-9 Antibody Attenuates Airway Inflammation in Murine Asthma Models*
**作者**：Smith A, et al.
**摘要**：研究证明，中和IL-9的单克隆抗体可减少哮喘模型小鼠的气道嗜酸性粒细胞浸润和黏液分泌，提示IL-9是治疗Th2型炎症的潜在靶点。
2. **标题**：*IL-9 Blockade Suppresses Tumor Growth in T-cell Lymphoma*
**作者**：Zhang Y, et al.
**摘要**：通过靶向IL-9的抗体抑制IL-9/STAT3信号通路，可显著抑制T细胞淋巴瘤的增殖并诱导肿瘤细胞凋亡，为IL-9依赖性癌症提供新疗法。
3. **标题**：*IL-9 Neutralization Reduces Autoimmune Encephalomyelitis Severity*
**作者**：Brown K, et al.
**摘要**：在多发性硬化症动物模型中，抗IL-9抗体通过调节Th17/Treg细胞平衡减轻中枢神经系统炎症，表明IL-9在自身免疫疾病中的关键作用。
4. **标题**：*Dual Role of IL-9 in Allergic Dermatitis: Pro-inflammatory and Regulatory Effects*
**作者**：Lee S, et al.
**摘要**：研究发现IL-9抗体可缓解过敏性皮炎模型的皮肤炎症，但过度抑制可能导致免疫调节功能受损，提示需精准调控IL-9靶向治疗。
(注：以上为模拟文献，实际研究需通过PubMed、Web of Science等数据库检索真实论文。)
Interleukin-9 (IL-9), a pleiotropic cytokine in the interleukin family, is primarily produced by activated T-helper 2 (Th2) cells, mast cells, and innate lymphoid cells. It plays a multifaceted role in immune regulation, particularly in allergic inflammation, autoimmune disorders, and anti-parasitic responses. IL-9 exerts its effects by binding to the IL-9 receptor (IL-9R), a heterodimer composed of IL-9Rα and the common γ-chain, activating downstream signaling pathways like JAK/STAT, MAPK, and PI3K. Dysregulated IL-9 signaling is implicated in pathologies such as asthma, atopic dermatitis, and inflammatory bowel disease, making it a therapeutic target.
IL-9 antibodies, including monoclonal and polyclonal variants, are designed to neutralize IL-9 or block its receptor interaction. Preclinical studies in murine models demonstrate that anti-IL-9 antibodies reduce airway hyperresponsiveness and eosinophilia in asthma, suppress tumor growth in certain cancers, and ameliorate colitis symptoms. However, clinical translation remains challenging due to IL-9's context-dependent roles—it may exhibit both pro-inflammatory and tissue-repair functions. Recent advances include engineered humanized antibodies with improved specificity and reduced immunogenicity. While early-phase clinical trials for asthma and atopic diseases show mixed efficacy, ongoing research explores combination therapies and biomarkers to stratify patients likely to benefit. IL-9 antibodies thus represent a promising yet complex tool for modulating immune-mediated diseases.
×
